Anavex Life Sciences's quarterly market cap
declined
from Dec. 2023 ($764.23 Mil) to Mar. 2024 ($425.61 Mil) and
declined
from Mar. 2024 ($425.61 Mil) to Jun. 2024 ($357.84 Mil).
Anavex Life Sciences's annual market cap
declined
from Sep. 2021 ($1,362.74 Mil) to Sep. 2022 ($804.37 Mil) and
declined
from Sep. 2022 ($804.37 Mil) to Sep. 2023 ($537.54 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anavex Life Sciences's Enterprise Value for Today is $565.05 Mil.
Anavex Life Sciences Market Cap Historical Data
The historical data trend for Anavex Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Anavex Life Sciences's Market Cap
For the Biotechnology subindustry, Anavex Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Market Cap falls into.
Anavex Life Sciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anavex Life Sciences's Market Cap for the fiscal year that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (NAS:AVXL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Anavex Life Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of Anavex Life Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVXL has been successfully added to your 